TELA
TELA Bio, Inc.
NasdaqGMUSDEQUITY
Healthcare
DELAYED
Last price
0.62
▼ 0.02 (2.89%)
MARKET · —
Price
Open
0.60
Prev close
0.64
Day high
0.68
Day low
0.63
Volume
59.77K
Market cap
$29.02M
P/E (TTM)
—
52W range
0.50 – 2.00
Trailing performance
Returnvs SPY
1W
+0.31%
+1.7%
1M
-9.14%
-12.9%
3M
-30.01%
-33.1%
6M
-9.90%
-21.0%
YTD
-45.25%
-57.5%
1Y
-61.78%
-81.8%
3Y
-92.82%
-167.0%
5Y
—
—
Price return only. Dividends are not reinvested, so total return on a dividend payer will be higher than shown.
Fundamentals
Market cap$29.02M
Enterprise value$56.51M
Revenue (TTM)$79.91M
Gross profit$54.57M
EBITDA$-33.01M
Net income$-41.18M
EPS (TTM)$-0.77
Free cash flow$-17.71M
Total cash$30.42M
Total debt$57.92M
Book value / share$-0.35
Shares outstanding44.89M
Float21.50M
Short % of float1.10%
Dividend yield—
Beta (5Y)1.36
Valuation & profitability ratios
Trailing P/E—
Forward P/E-1.24
PEG ratio—
Price / sales—
Price / book—
EV / revenue0.71
EV / EBITDA-1.71
Gross margin68.29%
Operating margin-48.12%
Profit margin-51.53%
Return on equity—
Return on assets-33.40%
Debt / equity—
Current ratio2.99
Fourteen ratios including P/E, PEG, EV/EBITDA, margins and return on equity.
Financial statements
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Total revenue | $80.28M | $69.30M | $58.45M | $41.42M |
| Cost of revenue | $0 | $0 | $0 | $0 |
| Gross profit | $0 | $0 | $0 | $0 |
| R&D | — | — | — | — |
| SG&A | — | — | — | — |
| Operating income | — | — | — | — |
| Pre-tax income | — | — | — | — |
| Tax provision | $0 | $0 | $0 | $0 |
| Net income | -$38.83M | -$37.84M | -$46.66M | -$44.30M |
| EBIT | $0 | $0 | $0 | $0 |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Cash & equivalents | — | — | — | — |
| Short-term investments | — | — | — | — |
| Net receivables | — | — | — | — |
| Inventory | — | — | — | — |
| Total current assets | — | — | — | — |
| Total assets | — | — | — | — |
| Total current liabilities | — | — | — | — |
| Long-term debt | — | — | — | — |
| Total liabilities | — | — | — | — |
| Retained earnings | — | — | — | — |
| Shareholder equity | — | — | — | — |
| Line item | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net income | -$38.83M | -$37.84M | -$46.66M | -$44.30M |
| Depreciation | — | — | — | — |
| Change in working capital | — | — | — | — |
| Operating cash flow | — | — | — | — |
| Capital expenditure | — | — | — | — |
| Investing cash flow | — | — | — | — |
| Dividends paid | — | — | — | — |
| Buybacks | — | — | — | — |
| Financing cash flow | — | — | — | — |
| Net change in cash | — | — | — | — |
Earnings
Reported vs expected · EPS
| Quarter | Est. | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | -0.18 | -0.20 | -12.4% |
| Dec 2025 | -0.18 | -0.17 | +6.6% |
| Sep 2025 | -0.20 | -0.19 | +5.0% |
Forward consensus
| Period | EPS | Analysts | Revenue | Growth |
|---|---|---|---|---|
| Current quarter | -0.18 | 5 | $20.01M | -0.9% |
| Next quarter | -0.13 | 5 | $21.24M | +1.8% |
| Current year | -0.70 | 5 | $79.64M | -0.8% |
| Next year | -0.52 | 5 | $87.11M | +9.4% |
Analyst targets & ownership
Mean target$2.10
High target$3.00
Low target$1.00
Implied upside238.27%
Analyst count5
ConsensusBUY
Strong buy / Buy1 / 3
Hold1
Sell / Strong sell0 / 0
Held by insiders8.87%
Held by institutions65.91%
Institutions holding50
Price targets, consensus spread, insider and institutional ownership.
Insider net activity
Net shares
0
Net selling
Buy transactions
0
0 shares
Sell transactions
0
—
Net transactions
0
Buys less sells
Sell : buy shares
—
Not enough filings
Insider-held shares
3.98M
Total on file
Insider transactions
| Date | Insider | Action | Shares | Value | Held |
|---|---|---|---|---|---|
| Aug 17, 26 | GETZ HEATHER C Chief Executive Officer |
BUY | 12.50K | $8.31K | Direct |
| Aug 14, 26 | GETZ HEATHER C Chief Executive Officer |
BUY | 15.00K | $10.47K | Direct |
| Aug 3, 26 | GETZ HEATHER C Chief Executive Officer |
STOCK | 500.00K | $0 | Direct |
| Jul 15, 26 | CAPPER JOSEPH H Director |
STOCK | 6.23K | $4.89K | Direct |
| Jul 15, 26 | PLOVANIC WILLIAM J. Director |
STOCK | 20.93K | $16.43K | Direct |
| Jun 9, 26 | NOHRA GUY P Director |
STOCK | 23.60K | $0 | Direct |
| Jun 9, 26 | THOMAS PAUL G Director |
STOCK | 23.60K | $0 | Direct |
| Jun 9, 26 | NEELS GUIDO J Director |
STOCK | 23.60K | $0 | Direct |
| Jun 9, 26 | CAPPER JOSEPH H Director |
STOCK | 23.60K | $0 | Direct |
| Jun 9, 26 | PLOVANIC WILLIAM J. Director |
STOCK | 11.68K | $0 | Direct |
| Jun 9, 26 | ROCCHIO BETTY JO Director |
STOCK | 11.68K | $0 | Direct |
| Feb 20, 26 | KOBLISH ANTONY Chief Executive Officer |
STOCK | 176.00K | $0 | Direct |
| Feb 20, 26 | CUCA ROBERTO Chief Operating Officer |
STOCK | 57.00K | $0 | Direct |
| Feb 20, 26 | TALMO PAUL Chief Technology Officer |
STOCK | 57.00K | $0 | Direct |
What this is, and what it is not
These are SEC Form 4 filings — officers, directors and 10% owners reporting their own trades in the company's stock. Filing is due within two business days of the transaction, so this lags reality by days, and the provider adds its own lag on top.
A sale is not automatically bearish. Executives sell on scheduled 10b5-1 plans, to cover tax on vesting equity, and to diversify. Purchases with cash are generally the more informative signal, and they are far rarer.
This does not include congressional or senate trading. That comes from STOCK Act disclosures filed with the Senate eFD system and the House Clerk, which this data source does not carry.
Officer and director trades in their own stock, straight from Form 4 filings.
Insider holders
| Name | Relation | Shares held | Latest |
|---|---|---|---|
BLIZARD JEFFREY |
President | 205.13K | Stock Award(Grant) |
CAPPER JOSEPH H |
Director | 29.83K | Stock Award(Grant) |
CUCA ROBERTO |
Chief Operating Officer | 257.38K | Stock Award(Grant) |
EW HEALTHCARE PARTNERS FUND 2, L.P. |
Beneficial Owner of more than 10% of a Class of Security | 7.71M | Purchase |
FIRESTONE GREGORY A |
Officer | 139.31K | Stock Award(Grant) |
GETZ HEATHER C |
Chief Executive Officer | 532.50K | Purchase |
KOBLISH ANTONY |
Chief Executive Officer | 586.21K | Stock Award(Grant) |
PLOVANIC WILLIAM J. |
Director | 44.53K | Stock Award(Grant) |
SMEYKAL MEGAN |
Officer | 66.87K | Stock Award(Grant) |
TALMO PAUL |
Chief Technology Officer | 173.44K | Stock Award(Grant) |
Moving averages & technicals
SMA 10
0.70
-11.15% from price
SMA 20
0.74
-12.21% from price
SMA 50
0.76
-15.33% from price
SMA 100
0.79
-21.52% from price
SMA 200
0.89
-27.10% from price
EMA 12
0.69
-10.66% from price
EMA 26
0.73
-14.98% from price
EMA 50
0.76
-18.31% from price
RSI (14)
40.1
Neutral
MACD (12,26,9)
-0.04
Hist -0.02
ATR (14)
0.11
16.57% of price
Realised vol 30D
97.3%
Annualised
Bollinger upper
0.94
20, 2σ
Bollinger lower
0.53
20, 2σ
50 / 200 cross
Death
0.76 vs 0.89
Trend bias
Below 200
-27.10%
Risk profile
Beta vs SPY
0.91
Less volatile than market
Correlation to SPY
0.13
Largely independent
Realised vol 30D
97.3%
Annualised
Market vol 1Y
12.9%
SPY, annualised
Max drawdown 1Y
-69.4%
Peak to trough
Max drawdown 5Y
-96.0%
Peak to trough
ATR 14
0.11
16.57% of price
Beta (reported)
1.36
5Y monthly, from filing
Unusual options activity
Nothing crossed the thresholds in the expiries we scanned.
That is the normal state — most contracts trade well inside their existing open interest.
That is the normal state — most contracts trade well inside their existing open interest.
Contracts trading at or above their open interest, ranked by notional and where the print landed.
Options analytics
Put / call volume
0.00
Call-heavy session
Put / call open interest
0.00
Positioning, not flow
Max pain
2.50
+286.8% from spot
ATM implied vol
—
Nearest strike to spot
Skew (10% OTM)
—
—
Call volume
19
Contracts, this expiry
Put volume
0
Contracts, this expiry
Heaviest call OI
5.00
16 contracts
Heaviest put OI
—
—
Max pain is the strike at which the largest dollar value of open contracts expires worthless. It describes current positioning; it is not a forecast and it moves as open interest changes.
Put/call ratios, max pain, implied volatility skew and where open interest is concentrated.
Options chain
Calls
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Puts
| Strike | Last | Bid | Ask | Vol | OI | IV |
|---|---|---|---|---|---|---|
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
| 000.00 | 0.00 | 0.00 | 0.00 | 0 | 0 | 0.0% |
Every listed expiry, both sides of the book, with volume, open interest and implied volatility.
Headlines
TELA Bio (TELA) Q2 2026 Earnings Call Transcript
Motley Fool · 3d ago
TELA Bio Inc (TELA) (Q2 2026) Earnings Call Highlights: Navigating PRS Headwinds and Strategic ...
GuruFocus.com · 12d ago
TELA Bio, Inc. Q2 2026 Earnings Call Summary
Moby · 12d ago
TELA Bio, Inc. (TELA) Reports Q2 Loss, Lags Revenue Estimates
Zacks · 12d ago
TELA Bio Reports Second Quarter 2026 Financial Results
GlobeNewswire · 12d ago
Earnings To Watch: TELA Bio Inc (TELA) Q2 2026 -- GF Value Sees 97% Upside
GuruFocus.com · 15d ago
Puma Biotech (PBYI) Q2 Earnings and Revenues Top Estimates
Zacks · 16d ago
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewswire · 17d ago
PRIVATE STRATEGY · BY QUALIFICATION
The same data. A different seat.
The research you are reading is the input layer for a discretionary options program we run for a small number of qualified investors. Minimum $1,000,000.